Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

Asmita Mishra, MD, Najla H Al Ali, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Mohamed A Kharfan-Dabaja, MD, Javier Pinilla-Ibarz, MD, PhD, Bryan J Little, Jeffrey E Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2816.

https://doi.org/10.1182/blood.V120.21.2816.2816

Published: 2012

Journal Articles

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Rami S. Komrokji, MD, Najla H Al Ali, Asmita Mishra, MD, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Jeffrey E Lancet, MD, Alan F. List, MD

Blood (2012) 120 (21): 3852.

https://doi.org/10.1182/blood.V120.21.3852.3852

Published: 2012

Journal Articles

Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes

Rami S. Komrokji, MD, Maria Corrales-Yepez, MD, Najla H Al Ali, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Javier Pinilla-Ibarz, MD, PhD, Jeffrey E Lancet, MD, Alan F. List, MD

Blood (2012) 120 (21): 3826.

https://doi.org/10.1182/blood.V120.21.3826.3826

Published: 2012

Journal Articles

Tobacco Use Influences Disease Outcome and AML Potential in Myelodysplastic Syndromes,

Rami S. Komrokji, MD, Dana E Rollison, PhD, Najla H Al Ali, M.S, Maria Corrales-Yepez, MD, Pearlie K Epling-Burnette, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 3790.

https://doi.org/10.1182/blood.V118.21.3790.3790

Published: 2011

Journal Articles

Obesity Is Poor Prognostic Factor in Lower Risk Myelodysplastic Syndrome

Asmita Mishra, MD, Dana E Rollison, PhD, Najla H Al Ali, M.S, Maria Corrales-Yepez, MD, Pearlie K Epling-Burnette, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2011) 118 (21): 5018.

https://doi.org/10.1182/blood.V118.21.5018.5018

Published: 2011

Journal Articles

Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes

Rami S. Komrokji, MD, Najla H Al Ali, M.S, Maria Corrales-Yepez, MD, Eric Padron, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 2777.

https://doi.org/10.1182/blood.V118.21.2777.2777

Published: 2011

Journal Articles

Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes

Maria Corrales-Yepez, MD, Mohamed A. Kharfan-Dabaja, MD, Jeffrey Lancet, MD, Alan F. List, MD, Eric Padron, MD, Dana Rollison, PhD, P.K. Epling-Burnette, PharmD, PhD, Ling Zhang, MD, Teressa Field, MD, Javier Pinilla-Ibarz, MD, Rami S. Komrokji, MD

Blood (2010) 116 (21): 4001.

https://doi.org/10.1182/blood.V116.21.4001.4001

Published: 2010

Journal Articles

Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes

Maria Corrales-Yepez, Jeffrey E. Lancet, MD, Alan F. List, MD, Mohamed A. Kharfan-Dabaja, MD, Teresa Field, MD, PhD, Eric Padron, MD, Rami S. Komrokji, MD

Blood (2010) 116 (21): 444.

https://doi.org/10.1182/blood.V116.21.444.444

Published: 2010

NARROW

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes

Tobacco Use Influences Disease Outcome and AML Potential in Myelodysplastic Syndromes,

Obesity Is Poor Prognostic Factor in Lower Risk Myelodysplastic Syndrome

Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes

Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes

Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only